|
Post by mssciguy on Sept 9, 2015 6:50:15 GMT -5
Lovely. 06:25 EDT MNKD theflyonthewall.com: MannKind downgraded to Underweight from Neutral at Piper Jaffray Piper Jaffray analyst Joshua Schimmer downgraded MannKind to Underweight from Neutral and cut his price target for shares to $1.50 from $4. Underweight is Piper's equivalent of a sell rating. Shares of MannKind closed yesterday up 19c to $4.07. Prescription trends for the company's inhaled insulin Afrezza "have been lackluster to say the least," Schimmer tells investors in a research note. Afrezza is being viewed as a "very niche product," the analyst writes after speaking to five primary care and endocrinology specialists with high volumes of diabetes patients. Schimmer believes MannKind has "vastly over-estimated" the commercial potential for Afrezza. He notes his new price tar get assumes 60% downside from current share levels. :theflyonthewall.com Same guy said that Afrezza would probably not be approved. No credibility. Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of the Afrezza Dreamboat insulin inhaler. Schimmer reported that it is "doubtful" for the company to gain positive recommendation from the advisory panel. The analyst commented that a closer read of the FDA staff briefing documents suggest that the agency "has enough concerns that only a cleanly positive vote will enable approval without additional requirements." Schimmer downgraded MannKind from Underweight to Neutral and drastically lowered the price target from $5.00 to $1.50. Read more: www.benzinga.com/analyst-ratings/analyst-color/14/03/4433155/shares-of-mannkind-plummet-prior-to-drug-advisory-meetin#ixzz3lF1HSRMy
|
|
|
Post by whanley7 on Sept 9, 2015 6:59:51 GMT -5
Didn't this firm just raise their price target from $3.50 to $4 like 3 weeks ago? Wtf? Talk about credibility.
|
|
|
Post by maytepper1 on Sept 9, 2015 7:00:55 GMT -5
|
|
|
Post by bioexec25 on Sept 9, 2015 7:01:16 GMT -5
Well that's just great! D these guys even look at the pk profile or user responses before they make these conclusions? Afrezza is too good to fail! I still believe overall but critically see very little evidence ... YET ... to disbute this. We argue it's all intentional with the slow launch, Insurance, etc. but I've never seen a therapeutic with seemingly this much potential being treated this way, regardless or launch strategy or tiering. We need real evidence either in take up or in a deal that lends support. I suppose they could be using niche to mean US market only. Because if Sny goes global then a small slice of a very very large pie is not what I would consider niche. Good luck to us all.
|
|
|
Post by peppy on Sept 9, 2015 7:01:24 GMT -5
Lovely. 06:25 EDT MNKD theflyonthewall.com: MannKind downgraded to Underweight from Neutral at Piper Jaffray Piper Jaffray analyst Joshua Schimmer downgraded MannKind to Underweight from Neutral and cut his price target for shares to $1.50 from $4. Underweight is Piper's equivalent of a sell rating. Shares of MannKind closed yesterday up 19c to $4.07. Prescription trends for the company's inhaled insulin Afrezza "have been lackluster to say the least," Schimmer tells investors in a research note. Afrezza is being viewed as a "very niche product," the analyst writes after speaking to five primary care and endocrinology specialists with high volumes of diabetes patients. Schimmer believes MannKind has "vastly over-estimated" the commercial potential for Afrezza. He notes his new price tar get assumes 60% downside from current share levels. :theflyonthewall.com hmmm, I had to look at the educational background. Attachment Deleted
|
|
|
Post by tbone on Sept 9, 2015 7:39:37 GMT -5
He averages -3% return on his calls on mnkd (and there are plenty). This should be good for 12 cents. Why everyone so sad? Happy Wednesday.
|
|
|
Post by bioexec25 on Sept 9, 2015 7:53:24 GMT -5
He averages -3% return on his calls on mnkd (and there are plenty). This should be good for 12 cents. Why everyone so sad? Happy Wednesday. True tbone. Fofos posted this from last year: Piper Jaffray - J.Schimmer on Afrezza upcoming FDA decision Schimmer downgraded MannKind from Underweight to Neutral and drastically lowered the price target from $5.00 to $1.50. Piper sees a 20% chance of clear positive vote, 60% chance of negative vote, 20% of split vote with “wide range of possible stock implications."
|
|
|
Post by garrett on Sept 9, 2015 8:00:11 GMT -5
It's obvious after Tuesday's large share price increase, Piper Jaffray analyst Joshua Schimmer got a call from his buddies (who have large short positions) to get his report out Wednesday morning to knock the stock down.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 9, 2015 8:02:46 GMT -5
So the next question is will anyone else pile on today and if so, who and what time? Might be a nice day to pick up some shares.
|
|
|
Post by tayl5 on Sept 9, 2015 8:14:51 GMT -5
The end result will be as binary as Schimmer's (bad) call on FDA approval: either Rx will rise enough to keep Sanofi engaged long term or it won't. He doesn't know the answer any more than we do, but we both get a clue every Friday.
|
|
|
Post by mnholdem on Sept 9, 2015 8:27:25 GMT -5
Josh ripped MannKind on May 8th. Then we watched as MNKD rose from a $3.56 opening on May 12 to $7.23 closing price on June 8. I'm hoping for a repeat... after all, some journalists are extremely gifted at bad timing.
|
|
|
Post by mssciguy on Sept 9, 2015 8:31:21 GMT -5
hmmm, I had to look at the educational background.
Money Doctor, not Doctor of Medicine
|
|
|
Post by newmnkdinvestor on Sept 9, 2015 8:48:02 GMT -5
hmmm, I had to look at the educational background.
Money Doctor, not Doctor of Medicine Harvard is Harvard Not defending him at all. This really pisses me off.
|
|
|
Post by mssciguy on Sept 9, 2015 8:51:34 GMT -5
|
|
|
Post by newmnkdinvestor on Sept 9, 2015 9:00:10 GMT -5
The point I am trying to make is a Harvard education whether its for business or medicine is still a ridiculous acoomplishment.
|
|